| Name | Title | Contact Details |
|---|
Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.
Areteia Therapeutics (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia`s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development including Phase 3 clinical trials of dexpramipexole in partnership with Population Health Partners` development unit, Validae Health.
Northwest Bioanalytical is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SignalChem Lifesciences Corporation is a privately owned biopharmaceutical company specializing in the discovery and development of kinase inhibitors as innovative therapies for cancer, inflammation and neurological diseases. The Company has a robust kinase platform encompassing 450 kinase targets and assays for the development and commercialization of unique therapies in many diseases. This vast resource empowers SLC’s scientists to identify novel drug candidates against kinase targets of interest. Another key part of SLC’s kinase drug development platform is KineCore, a kinase focused small molecule library that was designed and assembled in-house.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.